Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Pfizer (PFE) colorectal cancer therapy Braftovi as part of a drug combo indicates a favorable objective response rate in a ...

In a phase 2 study, treatment with the oral GLP-1 drug reduced patients' weight by 14.7% after just 36 weeks. In addition to diabetes and weight loss treatments, Eli Lilly is a big player in the ...

The FDA has officially approved Eli Lilly’s drug Omvoh for adult use in moderately ... a biotech company specializing in cancer treatments. The initial payment is expected to be around $1 ...

However, Eli Lilly recently surprised investors ... as it has several new drugs to treat conditions like cancer, ulcerative colitis, and Alzheimer's disease. If Lilly is correct in its assessment ...

Nico Chen’s rating is based on a combination of factors that highlight Eli Lilly & Co’s promising growth ... to positive developments in their drug pipeline, particularly the oral GLP-1 ...

Eli Lilly is experiencing explosive growth thanks ... According to data compiled by Coherent Market Insights, the global oncology drug market is expected to be worth $533 billion by 2031 ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly ... in the oncology market, Lilly also recently announced that it is acquiring a clinical stage drug known as ...